#GLP-1 class
Coverage of the GLP-1 receptor agonist family and its successors.
GLP-1 Agonists in Older Adults: Key Issues
Sarcopenia, polypharmacy, and limited age-specific data shape GLP-1 receptor agonist use in older adults with obesity and type 2 diabetes.
MASH drugs: resmetirom and semaglutide
Resmetirom and semaglutide now hold conditional approvals for MASH. Here is what the trial evidence shows and where gaps remain.
Real-world semaglutide: dose and dropout
A Danish study of 206 patients found 38% permanently stopped semaglutide within 12 months; 70% of continuers used doses below the 2.4 mg approved maximum.
SGLT2 and GLP-1 on arrhythmias: 32 trials
A 2026 network meta-analysis of 32 trials finds an exploratory VA signal for empagliflozin and consistent HHF benefits for SGLT2 inhibitors.
HbA1c alone cannot prove semaglutide parity
A July 2026 letter argues that matching semaglutide on HbA1c over 24 weeks does not establish full therapeutic interchangeability with the originator.
GLP-1 telehealth prescribing oversight
A Yale JAMA secret-shopper study flagged GLP-1 telehealth sites for thin clinical oversight. Here is what peer-reviewed evidence shows about platform quality.
Syringes for subcutaneous peptide injection
Syringe volume, needle gauge, and length each affect subcutaneous delivery. Here is what GLP-1 prescribing information and CDC injection safety guidance say.
SURMOUNT-OSA post-hoc: who benefits most
SURMOUNT-OSA post-hoc (Sleep, 2026): more-symptomatic patients saw larger subjective gains; objective AHI and weight changes were consistent across subgroups.
GLP-1 drugs in pediatric obesity
Liraglutide and semaglutide carry regulatory approval for adolescents with obesity. A 2026 review maps what the trials found and what gaps remain.
Incretin drugs for T2D: 2026 NMA results
A 2026 network meta-analysis of 102 trials and 98,693 T2D patients ranked tirzepatide first for glycaemic control and retatrutide first for weight loss.
How semaglutide works: the GLP-1 receptor
Semaglutide binds the GLP-1 receptor in the pancreas, brain, and gut. Here is what happens at each site.
Semaglutide side effects: what trials show
The STEP and SUSTAIN programmes documented semaglutide adverse events at scale. Here is what the data show, from GI effects to the thyroid boxed warning.